Assessment of Serum Cx3Cl1/Fractalkine Level in Han Chinese Girls with Anorexia Nervosa and its Correlation with Nutritional Status: A Preliminary Cross-Sectional Study
Restricted accessResearch articleFirst published online February, 2017
Assessment of Serum Cx3Cl1/Fractalkine Level in Han Chinese Girls with Anorexia Nervosa and its Correlation with Nutritional Status: A Preliminary Cross-Sectional Study
The chemokine (C-X3-C motif) ligand 1 (CX3CL1), also named fractalkine (FKN), has been implicated in psychiatric disorders and functions as a novel adipocytokine. However, no attention has been paid to the role of FKN in anorexia nervosa (AN). The current study was performed to explore FKN levels in AN to determine its role in the involvement of AN. A total of 96 girls aged 11–18 years with AN (n=34), healthy controls (HC; n=32) and simple obesity (OB, n=30) were enrolled in the cross-sectional study. Blood samples were collected during the fasting state. Serum FKN concentrations were determined using ELISA. The skinfold thickness (TSF) of the biceps and triceps as well as mid-arm muscle circumference (MAMC) were used to determine the nutritional status. Our results showed that serum FKN levels were significantly lower in the AN group than in the control and OB groups. After adjusting for body mass index (BMI), FKN concentrations in the AN group were statistically higher than in the HC and OB groups. Significant correlations between serum FKN and body weight, BMI, Cole index and serum insulin were observed. In addition, serum FKN levels were positively related to TSF and MAMC in all subjects. Serum FKN concentrations are attenuated in girls with AN compared with healthy adolescents and are positively related to nutritional status. The lower FKN levels may be regulated by nutrition status and response to starvation. After adjusting for BMI, higher FKN levels may reflect that persistent inflammation is present in patients with AN.
ZipfelS, MackI, BaurLA, . Impact of exercise on energy metabolism in anorexia nervosa. J Eat Disord2013;1:37. doi:10.1186/2050-2974-1-37
2.
ArcelusJ, MitchellAJ, WalesJ, . Mortality rates in patients with anorexia nervosa and other eating disorders: a meta-analysis of 36 studies. Arch Gen Psychiatry2011;68:724–31. doi:10.1001/archgenpsychiatry.2011.74
SolmiM, VeroneseN, FavaroA, . Inflammatory cytokines and anorexia nervosa: a meta-analysis of cross-sectional and longitudinal studies. Psychoneuroendocrinology2015;51:237–52. doi:10.1016/j.psyneuen.2014.09.031
5.
LeboyerM, OliveiraJ, TamouzaR, . Is it time for immunopsychiatry in psychotic disorders?Psychopharmacology (Berl)2016;233:1651–60. doi:10.1007/s00213-016-4266-1
6.
HoferMJ, CampbellIL. Immunoinflammatory diseases of the central nervous system—the tale of two cytokines. Br J Pharmacol2016;173:716–28. doi:10.1111/bph.13175
7.
Ahrén-MoongaJ, LekanderM, von BlixenN, . Levels of tumour necrosis factor-alpha and interleukin-6 in severely ill patients with eating disorders. Neuropsychobiology2011;63:8–14. doi:10.1159/000321832
8.
AgnelloE, MalfiG, CostantinoAM, . Tumour necrosis factor alpha and oxidative stress as maintaining factors in the evolution of anorexia nervosa. Eat Weight Disord2012;17:e194–9. doi:10.1007/BF03325347
9.
PinheiroAP, SullivanPF, BacaltchuckJ, . Genetics in eating disorders: extending the boundaries of research. Rev Bras Psiquiatr2006;28:218–25. doi:10.1590/S1516-44462006005000004
10.
Portela de SantanaML, da Costa Ribeiro JuniorH, Mora GiralM, . Epidemiology and risk factors of eating disorder in adolescence: a review. Nutr Hosp2012;27:391–401.
11.
BryantVL, SladeCA. Chemokines, their receptors and human disease: the good, the bad and the itchy. Immunol Cell Biol2015;93:364–71. doi:10.1038/icb.2015.23
12.
BajettoA, BonaviaR, BarberoS, . Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem2002;82:1311–29. doi:10.1046/j.1471-4159.2002.01091.x
13.
ZlotnikA, YoshieO. Chemokines: a new classification system and their role in immunity. Immunity2000;12:121–7. doi:10.1016/S1074-7613(00)80165-X
14.
D'HaeseJG, DemirIE, FriessH, . Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin Ther Targets2010;14:207–19. doi:10.1517/14728220903540265
15.
BazanJF, BaconKB, HardimanG, . A new class of membrane-bound chemokine with a CX3C motif. Nature1997;385:640–4. doi:10.1038/385640a0
16.
StovingRK, HangaardJ, Hansen-NordM, . A review of endocrine changes in anorexia nervosa. J Psychiatr Res1999;33:139–52. doi:10.1016/S0022-3956(98)00049-1
17.
BrichardSM, DelporteML, LambertM. Adipocytokines in anorexia nervosa: a review focusing on leptin and adiponectin. Horm Metab Res2003;35:337–42. doi:10.1055/s-2003-41353
18.
ShahR, HinkleCC, FergusonJF, . Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes2011;60:1512–18. doi:10.2337/db10-0956
19.
LeeYS, MorinagaH, KimJJ, . The fractalkine/CX3CR1 system regulates β cell function and insulin secretion. Cell2013;153:413–25. doi:10.1016/j.cell.2013.03.001
20.
XueyaoY, SaifeiZ, DanY, . Circulating fractalkine levels predict the development of the metabolic syndrome. Int J Endocrinol2014;2014:715148. doi:10.1155/2014/715148
21.
MorariJ, AnheGF, NascimentoLF, . Fractalkine (CX3CL1) is involved in the early activation of hypothalamic inflammation in experimental obesity. Diabetes2014;63:3770–84. doi:10.2337/db13-1495
22.
ShahR, O'NeillSM, HinkleC, . Metabolic effects of CX3CR1 deficiency in diet-induced obese mice. PLoS ONE2015;10:e0138317. doi:10.1371/journal.pone.0138317
23.
PolyakA, FerencziS, DenesA, . The fractalkine/CX3CR1 system is implicated in the development of metabolic visceral adipose tissue inflammation in obesity. Brain Behav Immun2014;38:25–35. doi:10.1016/j.bbi.2014.01.010
24.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. Washington, DC: American Psychiatric Association, 2013.
25.
ColeTJ, LobsteinT. Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. Pediatr Obes2012;7:284–94. doi:10.1111/j.2047-6310.2012.00064.x
26.
NelsonEE, HongCD, PesceAL, . Anthropometric norms for the dialysis population. Am J Kidney Dis1990;16:32–7. doi:10.1016/S0272-6386(12)80782-7
27.
NooriN, KoppleJD, KovesdyCP, . Mid-arm muscle circumference and quality of life and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol2010;5:2258–68. doi:10.2215/CJN.02080310
28.
FrancoL, WilliamsFM, TrofimovS, . Elevated plasma fractalkine levels are associated with higher levels of IL-6, Apo-B, LDL-C and insulin, but not with body composition in a large female twin sample. Metabolism2013;62:1081–7. doi:10.1016/j.metabol.2013.02.001
29.
FongAM, RobinsonLA, SteeberDA, . Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med1998;188:1413–19. doi:10.1084/jem.188.8.1413
30.
SadagurskiM, NorquayL, FarhangJ, . Human IL-6 enhances leptin action in mice. Diabetologia2010;53:525–35. doi:10.1007/s00125-009-1580-8
31.
IwasaT, MatsuzakiT, MurakamiM, . Changes in responsiveness of appetite, leptin and hypothalamic IL-1β and TNF-α to lipopolysaccharide in developing rats. J Neuroimmunol2011;236:10–16. doi:10.1016/j.jneuroim.2011.04.004
32.
InuiA. Eating behavior in anorexia nervosa—an excess of both orexigenic and anorexigenic signalling?Mol Psychiatry2001;6:620–4. doi:10.1038/sj.mp.4000944
33.
NakaiY, HamagakiS, TakagiR, . Plasma concentrations of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors in patients with anorexia nervosa. J Clin Endocrinol Metab1999;84:1226–8.
34.
Scheede-BergdahlC, WattHL, TrutschniggB, . Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia?Clin Nutr2012;31:85–8. doi:10.1016/j.clnu.2011.07.010
35.
BarberJ, SheeranT, MulherinD. Anti-tumour necrosis factor treatment in a patient with anorexia nervosa and juvenile idiopathic arthritis. Ann Rheum Dis2003;62:490–1. doi:10.1136/ard.62.5.490
36.
SolmiM, SantonastasoP, CaccaroR, . A case of anorexia nervosa with comorbid Crohn's disease: beneficial effects of anti-TNF-α therapy?Int J Eat Disord2013;46:639–41. doi:10.1002/eat.22153
37.
MerendinoRA, Di PasqualeG, De LucaF, . Involvement of fractalkine and macrophage inflammatory protein-1 alpha in moderate-severe depression. Mediators Inflamm2004;13:205–7. doi:10.1080/09511920410001713484
38.
WadeTD, Fairweather-SchmidtAK, ZhuG, . Does shared genetic risk contribute to the co-occurrence of eating disorders and suicidality?Int J Eat Disord2015;48:684–91. doi:10.1002/eat.22421
